RIMLS highlights 2017
Nicoline Hoogerbrugge Bridging science and healthcareNicoline Hoogerbrugge is the coordinator of a new European Reference Network. Here, she talks about here role in bridging science and healthcare.
Robert Sauerwein The slow and steady road to a malaria vaccine
Robert Sauerwein and his team achieved significant results regarding a new malaria vaccine. Here, he describes the potential impact of his research for the foreseeable future.read interview
Marien de Jonge Venture Challenge AwardAccording to the Venture Challenge Jury the technological innovation of X-Heal Diagnostics addresses the worldwide issues of Antimicrobial Resistance (AMR) by its quick and specific detection. The X-halyzer technology, a patented diagnostic technology that allows specific detection of bacteria from exhaled air within one hour, directly enabling targeted treatment for patients with chronic lung diseases, has been developed by researchers from Radboud University Medical Center and Innosieve Diagnostics BV.
Marien de Jonge of the theme Inflammatory disorders states: “Our ambition is to market our X-halyzer technology for different indications and target groups, such as the diagnosis of lung infections in cystic fibrosis patients and diagnosis of tuberculosis"
Chronic Obstructive Pulmonary Disease (COPD) is a chronic respiratory condition affecting 380 million patients worldwide leading to severe morbidity and mortality. These patients are vulnerable for recurrent infection of the airways leading to exacerbations or lung attacks, characterized by severe shortness of breath and irreversible lung damage. Prevention or shortening the lung attacks is pivotal to maintain the quality of life for COPD patients, for which early diagnosis of infection is required. Current diagnostic methods take 2 to 3 days, while the patient requires treatment within hours upon arrival in the hospital. As a consequence, most patients are treated empirically with broad spectrum antibiotics.
Second left: Marien de Jonge
ERN22 February 2017
Radboudumc is one of the leading partners in the new European Reference Network eUROGEN by participation in all 3 workstreams. This Network involved 29 Health care Providers (HCP) from 11 European Member States and is part of the European Health care innovation program for Rare diseases.
The ERN for rare and complex urogenital diseases and conditions (eUrogen) is comprised of 3 workstreams (WS). Focusing on diagnosis and treatment, 'ensuring continuity of care from childhood throughout life': WS1- rare uro-recto-genital congenital anomalies; WS2 - functional urogenital conditions requiring highly specialised surgery and WS3 - rare urogenital tumours. eUROGEN will improve diagnosis, create more equitable access to high quality treatment and care for patients with rare urogenital diseases and complex conditions needing highly specialised surgery. eUROGEN has worked with the European Association of Urology in close partnership with all national European urological societies. They have 3 broad WS to ensure that as many of our patients as possible can receive high quality specialist care from birth through to the end of life.
The RIHS and RIMLS researchers who are involved in this network are Wout Feitz, Nel Roeleveld, Iris van Rooij, Ivo de Blaauw, John Heesakkers, Hans Langenhuijsen, Hedi Claahsen, Marlies Cornelissen, Toin van Kuppevelt. Willeke Daamen and Egbert Oosterwijk, themes Reconstructive and regenerative medicine and Urological cancers.
Communication toolkit for ERN Members, ERN BoMS, national focal points and Commission Representations you can find here.
Best Master's program in life sciences
The Research Master Molecular Mechanisms of Disease (MMD) of the Radboudumc is the best Master's program in life sciences in the Netherlands according to the Dutch Master's program information guide "Keuzegids Masters 2017". It is the third time that MMD is distinguished as a "Top Master".read more
Best Master's program in life sciences28 February 2017
The Research Master Molecular Mechanisms of Disease (MMD) of the Radboudumc is the best Master's program in life sciences in the Netherlands according to the Dutch Master's program information guide "Keuzegids Masters 2017".
It is the fourth time that MMD is distinguished as a "Top Master". MMD is part of the graduate school of the Radboud Institute of Molecular Life Sciences (RIMLS).
Each year an international group of maximally 24 students receives an intensive education and training towards a career in the molecular life sciences.